title: Erythropoietin attenuates hyperoxia-induced lung injury by down-modulating inflammation in neonatal rats.
abstract: This study was done to determine whether recombinant human erythropoietin (rhEPO) treatment could attenuate hyperoxia-induced lung injury, and if so, whether this protective effect is mediated by the down-modulation of inflammation in neonatal rats. Newborn Sprague Dawley rat pups were subjected to 14 days of hyperoxia (>95% oxygen) within 10 hr after birth. Treatment with rhEPO significantly attenuated the mortality and reduced body weight gain caused by hyperoxia. With rhEPO treatment, given 3 unit/gm intraperitoneally at 4th, 5th, and 6th postnatal day, hyperoxia- induced alterations in lung pathology such as decreased radial alveolar count, increased mean linear intercept, and fibrosis were significantly improved, and the inflammatory changes such as myeloperoxidase activity and tumor necrosis factor-alpha expression were also significantly attenuated. In summary, rhEPO treatment significantly attenuated hyperoxia-induced lung injury by down-modulating the inflammatory responses in neonatal rats.
authors.affiliation: Department of Pediatrics, College of Medicine, Korea University, Seoul, Korea.
authors.forename: Jang Hoon
authors.initials: JH
authors.lastname: Lee
authors.forename: Dong Kyung
authors.initials: DK
authors.lastname: Sung
authors.forename: Soo Hyun
authors.initials: SH
authors.lastname: Koo
authors.forename: Bong Kyung
authors.initials: BK
authors.lastname: Shin
authors.forename: Young Sook
authors.initials: YS
authors.lastname: Hong
authors.forename: Chang Sung
authors.initials: CS
authors.lastname: Son
authors.forename: Joo Won
authors.initials: JW
authors.lastname: Lee
authors.forename: Yun Sil
authors.initials: YS
authors.lastname: Chang
authors.forename: Won Soon
authors.initials: WS
authors.lastname: Park
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D019610:Cytoprotection; D004195:Disease Models, Animal; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D018496:Hyperoxia / Q000473:pathology*; D007249:Inflammation / Q000188:drug therapy*; D008168:Lung / Q000187:drug effects* / Q000473:pathology; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins; D015996:Survival Rate; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
chemical_list: D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D004921:Erythropoietin; D009195:Peroxidase